Fig. 7: Model of therapeutic ATAD2 inhibition.
From: ATAD2 is a driver and a therapeutic target in ovarian cancer that functions by upregulating CENPE
ATPase family AAA domain-containing 2 (ATAD2) promotes ovarian cancer tumor growth and progression by regulating the expression of centromere protein E (CENPE), which prevents cycle arrest and apoptosis. ATAD2 and CENPE can both be targeted via small-molecule inhibitors, either alone or in combination, to provide effective ovarian cancer therapy.
